×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Ovarian Cancer

Feature Video
Dr Shannon Westin, a clinical investigator at the MD Anderson Cancer Center, discusses PARP inhibition for patients with deleterious or suspected deleterious germline BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
Brielle Urciuoli
PARP inhibitors continue to impress in the ovarian cancer space, as findings from the recent phase 3 SOLO-1 trial showed that Lynparza (olaparib) showed clinically-meaningful improvement in progression-free survival (PFS) when used in the first-line maintenance setting.
David O'Malley, M.D.
Folate receptor alpha was a promising biomarker when it came to treatment with mirvetuximab soravtansine.
Katie Kosko
A recent review of data found that 79 percent of patients with ovarian cancer felt uncomfortable raising psychological and emotional concerns during their consultations.
Kristie L. Kahl
In the QUADRA study, treatment with Zejula (niraparib) demonstrated durable responses among women with relapsed or refractory ovarian cancer, regardless of BRCA mutation.
Kristie L. Kahl
Lynch syndrome – a hereditary condition that increases a person’s risk for developing several types of cancer – is common among people with microsatellite instability-high (MSI-H) tumors, linking it to several new cancer types, according to large genomic study results presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
Brielle Urciuoli
The Food and Drug Administration approved a combination of Avastin (bevacizumab) plus the chemotherapy agents carboplatin and paclitaxel, followed by Avastin alone, for the treatment of patients with advanced ovarian cancer who have had surgical resection.
Brielle Urciuoli
The FDA approved the Paxman Scalp Cooling System for patients with solid tumors who wish to prevent chemotherapy-related hair loss.
Brielle Urciuoli
Although genetic testing could be crucial in developing treatment plans and improving outcomes in women with ovarian and breast cancer, less than 20 percent of eligible patients actually get tested, according to Mike Janicek, M.D.
Maurie Markman, M.D.
The field of ovarian cancer is changing rapidly, and moving toward an era of precision medicine.
Amy Roberts & Janine DeFeo
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable